Picture of Yourgene Health logo

YGEN Yourgene Health News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

REG - Yourgene Health PLC - Directorate Change

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230522:nRSV0972Aa&default-theme=true

RNS Number : 0972A  Yourgene Health PLC  22 May 2023

Yourgene Health plc

("Yourgene", the "Group" or the "Company")

 

Directorate Change

 

Manchester, UK - 22 May 2023: Yourgene (AIM: YGEN), a leading international
molecular diagnostic group, announces the reappointment of Dr. Joanne Mason,
Chief Scientific Officer, as a Director of the Company with immediate effect.

 

Dr. Mason has been leading the development of Yourgene's next generation
molecular diagnostics, in particular in the area of reproductive health,
helping the Company deliver on its new product roadmap and commercial success.
Given Dr Mason's background and experience in this field, she is playing an
increasingly pivotal role for the Company in highlighting the technical
benefits of the Company's offerings to potential and existing customers, and
her expertise provides an important complement to the skills and understanding
of the wider Board.

 

Disclosures in accordance with the AIM Rules

 

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of Dr. Joanne Nicola Mason (aged
49):

 

 Current appointments    Former appointments in the past 5 years
 Yourgene Health UK Ltd  Yourgene Health plc

 

 

Dr. Mason holds 7,509,480 ordinary shares and 1,000,000 options over new
ordinary shares in the Company.

 

There are no further disclosures required in accordance with AIM Rule 17 and
Schedule Two paragraph (g) of the AIM Rules for Companies.

 

 

This announcement contains inside information for the purposes of the UK
Market Abuse Regulation.

The Directors of the Company take responsibility for this announcement.

 

 

 Yourgene Health plc                                Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                  investors@yourgenehealth.com (mailto:investors@yourgenehealth.com)
 Joanne Cross, Director of Marketing

 Cairn Financial Advisers LLP (NOMAD)               Tel: +44 (0)20 7213 0880
 Liam Murray / Ludovico Lazzaretti

 Singer Capital Markets (Corporate Broker)          Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Walbrook PR Ltd (Media and Investor Relations)     Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
                                                    (mailto:yourgene@walbrookpr.com)
 Paul McManus / Alice Woodings / Lianne Applegarth  Mob: 07980 541 893 / 07407 804 654/ 07584 391 303

 

About Yourgene Health

Yourgene Health is an international integrated technologies and services
business, enabling the delivery of genomic medicine. The Group works in
partnership with global leaders in DNA technology to advance diagnostic
science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic and screening solutions, for reproductive health
and precision medicine. The Group's portfolio of in vitro diagnostic products
includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other
genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy
tests and DPYD genotyping assays.

 

Building on our expertise in genomic technology, Yourgene's Ranger®
Technology offers next generation size selection with a range of sample
preparation platforms for dynamic target enrichment. Ranger® Technology can
be utilised to improve workflows and performance in multiple applications
including NIPT, oncology, infectious disease testing and gene synthesis.

 

Yourgene Genomic Services offers a clinical service from UK and Taiwan
focusing on precision medicine and reproductive health, including NIPT.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN".

 

For more information visit https://yourgenehealth.com/
(https://yourgenehealth.com/) and follow us on twitter @Yourgene_Health.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPUCWAUPWGQB

Recent news on Yourgene Health

See all news